Pharmaceuticals

Active ingredients for human or veterinary use, widely used worldwide, can be found in the natural environment. Therefore, the environmental risk assessment (ERA) is described in the pharmaceutical regulations and is an integral part of a non-eliminatory process of implementing a pharmaceutical product in the market.

These procedures involve the new active ingredients and active ingredients that are already in the market with extension of use. They apply to the US and European market.

In the Staphyt laboratory, we performed physicochemical and ecotoxicological tests and evaluated the environmental fate of the molecules, in particular according to the EMA* (Guideline on the environmental risk assessment of 5 medicinal products for human use) directive.